RPS6KB1 and metabolic dysfunction-associated steatotic liver disease: Increased Sestrin 2 potentiates AMPK activation and suppresses mTORC1-S6K activity in the liver, alleviating insulin resistance and obesity associated nonalcoholic fatty liver disease (NAFLD) pathologies including steatohepatitis and hepatic fibrosis.